peptidylprolyl isomerase A pseudogene 44Genealiases: []
Q-omics provides the consensus-scored PPIAP44 profile across patient tissues and cancer cell-line models. PPIAP44 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PPIAP44 is differentially expressed in 5, with the highest sampling consensus in KIRP. Additionally, PPIAP44 RNA expression shows 5,226 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KIRP, and TGCT as cancer lineages where PPIAP44 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAP44 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAP44 survival associations across molecular data types. PPIAP44 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAP44 RNA expression–survival associations across cancer types. High PPIAP44 expression shows unfavorable associations in MESO, STAD, PAAD, ACC and LIHC, but favorable associations in CESC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PPIAP44 RNA expression.
This table summarizes PPIAP44 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAP44. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAP44 shows higher tumor expression in KIRP, LUAD, LIHC, LUSC and BRCA. The KIRP box plot shows higher PPIAP44 RNA expression in tumor versus normal tissue (log2 FC = +0.147, t-test p = .012).
This table shows molecular features associated with PPIAP44 in patient tissues and cancer cell lines. In patient samples, PPIAP44 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
